Amicus Therapeutics, Inc.

Amicus Therapeutics is a biotechnology company whose core business model relies on animal testing to develop and gain regulatory approval for its drug candidates. The company’s lead investigational therapies for rare diseases, such as those for Fabry disease and Pompe disease, require extensive preclinical testing in animals to demonstrate safety and efficacy before human trials can proceed. This dependence on animal experimentation is inherent to its pharmaceutical development process.

Evidence submitted in legal proceedings indicates that animals used in such testing endure conditions that may constitute severe suffering. In a 2021 court filing, Amicus acknowledged that evidence shows animals subject to experimentation endure conditions similar to or worse than those previously found by federal courts to constitute animal cruelty. While specific, recent USDA inspection records for Amicus were not publicly available in the gathered evidence, broader industry oversight has been highlighted by groups including the Humane Society of the United States, which in 2019 brought systemic animal welfare violations in the pharmaceutical testing sector to the attention of the SEC.